A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://www.nature.com/articles/6601285.pdf
Reference16 articles.
1. Basu A, Lazo JS (1992) Sensitization of human cervical carcinoma cells to cisdiamminedichloroplatinum(II) by bryostatin 1. Cancer Res 52: 3119–3124
2. Benedetti Panici P, Greggi S, Amoroso M, Scambia G, Battaglia FA, Gebbia V, Salerno G, Paratore MP, Mancuso S (2001) A combination of platinum and tamoxifen in advanced ovarian cancer failing platinum-based chemotherapy: results of a Phase II study. Int J Gynecol Cancer 11: 438–444
3. Clamp A, Jayson GC (2002) The clinical development of the bryostatins. Anti-Cancer Drugs 13: 673–683
4. Gehan A (1961) The determination of the number of patients required in a preliminary and a follow up trial of a new chemotherapeutic agent. J Chronic Dis 13: 346–353
5. Jayson GC, Crowther D, Prendiville J, McGown AT, Scheid C, Stern P, Young R, Brenchley P, Chang J, Owen S (1995) A phase I trial of bryostatin-1 in patients with advanced malignancy using a 24 h intravenous infusion. Br J Cancer 72: 461–468
Cited by 35 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Bryostatin-1: a promising compound for neurological disorders;Frontiers in Pharmacology;2023-06-07
2. Activators and Inhibitors of Protein Kinase C (PKC): Their Applications in Clinical Trials;Pharmaceutics;2021-10-20
3. Preclinical and Clinical Studies on Bryostatins, A Class of Marine-Derived Protein Kinase C Modulators: A Mini-Review;Current Topics in Medicinal Chemistry;2020-06-01
4. Prodrugs of PKC modulators show enhanced HIV latency reversal and an expanded therapeutic window;Proceedings of the National Academy of Sciences;2020-05-05
5. Preclinical and Clinical Studies on Bryostatins, A Class of Marinc-Derived Protein Kinase C Modulators: A Mini-Review;CURR TOP MED CHEM;2020
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3